|Dr. David M. Goldenberg||Founder, Chief Patent Officer, Chief Scientific Officer & Director||779.44k||1.21M||79|
|Mr. Michael R. Garone||CFO, Principal Accounting Officer & VP of Fin.||4.62k||N/A||58|
|Mr. Michael F. Pehl||Pres, CEO & Director||N/A||N/A||52|
|Ms. Phyllis Parker||Director of Admin.||N/A||N/A||N/A|
|Dr. Chau Cheng||Sr. Director of Investor Relations & Corp. Sec.||N/A||N/A||N/A|
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Immunomedics, Inc.’s ISS Governance QualityScore as of December 1, 2017 is 6. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 1; Compensation: 9.